LARVOL, a providesr of SaaS solutions to support the data and intelligence needs of the pharmaceutical and biotech industry, announced on Tuesday that it has appointed Mark Lagunowich as vice president, Global Sales.
With more that 30 years of experience in the life science industry, Lagunowich most recently led the Americas Life Science Sales Team for Clarivate Analytics.
Previously, Lagunowich worked as Global VP of Sales at Sparta Systems for eight years, selling a wide variety of business solutions to pharmaceutical, medical device, and clinical research (CRO) companies.
Lagunowich's appointment adds to several important new hires for LARVOL, including HR and Marketing leadership roles, as the company prepares to launch additional oncology-focused solutions in 2021. These include VIEW, a social listening platform aimed at capturing the conversations of oncology opinion leaders on Twitter, which will launch at ScaleUp 360 in April, along with CLIN, a complete database of immuno-oncology clinical trial data that will also launch in spring this year.
Insilico Medicine signs multi-year research and development collaboration with Servier
MemorialCare hospitals recognised in 2026 Women's Choice Awards
International Isotopes Inc to change name to Radnostix Inc
Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma
Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism
Sensiva Health names new chief operating officer
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74
ABL Bio receives upfront payment and equity investment from Eli Lilly
Harbour BioMed and Yantai Lannacheng Biotechnology form collaboration to advance next-gen RDCs
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer